BlackRock Group’s Gyre Therapeutics GYRE Stock Holding History

BlackRock Group’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-20	Closed	-$85K	–	2719
2013 Q3	$85K	Buy	+20	New	+$80.5K	﹤0.01%	2631

Other funds holding GYRE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock Group's GYRE Position: Q4 2013 in Review

BlackRock Group sold out of Gyre Therapeutics (GYRE) in Q4 2013, closing a stake of 20 shares — an estimated $85K sold.

BlackRock Group first reported a position in GYRE in Q3 2013 and held it in 1 quarter. The position peaked at $85K in Q3 2013. 74 funds tracked by Wall St. Rank hold GYRE as of Q4 2013.

BlackRock Group reported no remaining Gyre Therapeutics position as of Q4 2013 after selling out during the quarter.
BlackRock Group sold 20 Gyre Therapeutics shares in Q4 2013, an estimated $85K.
BlackRock Group first reported a position in Gyre Therapeutics in Q3 2013 and held it in 1 quarter.
BlackRock Group's Gyre Therapeutics position peaked at $85K in Q3 2013.
74 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2013.

Based on BlackRock Group's 13F filing for Q4 2013, filed 12 Feb 2014.